Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merrimack Pharmaceuticals has initiated patient enrollment in randomized Phase 2 clinical trial of MM-121 with Paclitaxel in HER2-negative breast cancer patients.
Subscribe to our email newsletter
MM-121 is a fully human monoclonal antibody that targets ErbB3.
The Phase 2 study will assess efficacy of MM-121 in combination with paclitaxel as compared to treatment with paclitaxel alone when administered as part of a neoadjuvant treatment regimen.
The company expects to enroll around 200 patients.